Glaxosmithkline Pharmaceuticals Ltd
₹2594.40
(-2.78%)
Fri, 13 Feb 2026, 01:14 pm
Health Technology
Pharmaceuticals: Major
24.5KGlaxosmithkline Pharmaceuticals Price to Sales Ratio (P/S)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 30.84 | 26.86 | 21.30 | 20.99 | 27.25 | 34.31 | 26.06 | 32.65 | 52.62 | 77.72 | 85.58 | 68.79 | 50.36 | 49.44 | 226.34 | 68.13 | 16.62 | 36.73 | 55.80 | 52.55 |
| Price to book ratio | 9.96 | 8.19 | 6.32 | 6.17 | 7.64 | 10.17 | 8.47 | 9.14 | 12.74 | 15.76 | 14.75 | 11.54 | 8.59 | 10.29 | 11.59 | 16.51 | 10.58 | 12.88 | 18.52 | 24.98 |
| Price to sales ratio | 6.39 | 6.23 | 5.46 | 5.77 | 7.15 | 9.01 | 6.75 | 6.85 | 9.94 | 10.96 | 11.72 | 7.97 | 6.15 | 7.04 | 6.54 | 8.34 | 8.59 | 6.90 | 9.53 | 13 |
| Price to cash flow ratio | 25 | 33.22 | 22.30 | 23.29 | 22.26 | 35.68 | 35 | 38.66 | 55.81 | 55.80 | 114.58 | 72.50 | 32.96 | 46.31 | 38.01 | 38.58 | 32.97 | 40.99 | 48.75 | 34.62 |
| Enterprise value | 95.7B | 98.33B | 85.75B | 87.64B | 119.09B | 178.4B | 143.6B | 162.32B | 233.01B | 269.14B | 308.03B | 222.7B | 163.69B | 208.49B | 200.54B | 232.78B | 253.41B | 207.73B | 310.57B | 462.29B |
| Enterprise value to EBITDA ratio | 21.73 | 20.07 | 15.54 | 15.03 | 17.64 | 22.91 | 17.81 | 19.99 | 44.45 | 54.59 | 61.43 | 51.73 | 31.16 | 33.87 | 29.47 | 38.46 | 32.81 | 25.31 | 33.93 | 38.86 |
| Debt to equity ratio | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
| Return on equity % | 33.21 | 34.03 | 31.68 | 31.31 | 29.77 | 30.94 | 32.38 | 28.51 | 24.11 | 19.43 | 18.75 | 16.08 | 17.26 | 21.22 | 4.71 | 17.42 | 18.30 | 27.59 | 33.53 | 49.75 |
Glaxosmithkline Pharmaceuticals Ltd Price to Sales Ratio
The Glaxosmithkline Pharmaceuticals Ltd Price to Sales Ratio is a key financial metric used by investors to evaluate Glaxosmithkline Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Glaxosmithkline Pharmaceuticals Ltd Price to Sales Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Glaxosmithkline Pharmaceuticals Ltd (NSE: GLAXO, BSE: 500660) is currently trading at ₹2594.40, with a market capitalization of ₹451.8B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Glaxosmithkline Pharmaceuticals Ltd Price to Sales Ratio is essential for fundamental analysis.
Glaxosmithkline Pharmaceuticals Ltd Price to Sales Ratio Current Value
The current Glaxosmithkline Pharmaceuticals Ltd Price to Sales Ratio stands at 13.
The latest Glaxosmithkline Pharmaceuticals Ltd Price to Sales Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Glaxosmithkline Pharmaceuticals Ltd Price to Sales Ratio Historical Trend
The Glaxosmithkline Pharmaceuticals Ltd Price to Sales Ratio has shown the following historical trend:
- 2024: 13
- 2023: 9.53
- 2022: 6.90
- 2021: 8.59
- 2020: 8.34
The recent rise in Glaxosmithkline Pharmaceuticals Ltd Price to Sales Ratio suggests strengthening valuation trends and improving market sentiment.
What Glaxosmithkline Pharmaceuticals Ltd Price to Sales Ratio Indicates for Investors
The Glaxosmithkline Pharmaceuticals Ltd Price to Sales Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/S ratio helps evaluate valuation relative to company revenue.
Glaxosmithkline Pharmaceuticals Ltd Price to Sales Ratio Analysis Summary
The Glaxosmithkline Pharmaceuticals Ltd Price to Sales Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Glaxosmithkline Pharmaceuticals Ltd Price to Sales Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Glaxosmithkline Pharmaceuticals Ltd Price to Sales Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800